nanoapalutamide

Nanoapalutamide is a nanocrystalline-enabled oral formulation of **apalutamide**, a nonsteroidal antiandrogen (NSAA) that acts as a potent selective androgen receptor (AR) antagonist. Nanoapalutamide uses nanotechnology to improve drug loading, resulting in smaller tablets and potentially faster absorption and higher serum concentrations compared to conventional amorphous solid dispersion (ASD) formulations. The mechanism of action is via direct antagonism of the androgen receptor, preventing nuclear translocation, DNA binding, and androgen-dependent gene transcription in prostate tumor cells. Nanoapalutamide is developed to provide improved patient convenience and performance over standard apalutamide tablets but is not itself a novel molecular entity. The underlying indication for apalutamide—and thus nanoapalutamide—is prostate cancer, specifically metastatic castration-sensitive and non-metastatic castration-resistant prostate cancer. The developer is Nanoform Finland, which specializes in nanoforming pharmaceutical compounds[19]. There is preclinical and early clinical validation for its improved pharmacokinetic profile, but there are no reported advanced clinical trial results as of late 2025.

Brand names

nanoapalutamide

Other names

nanocrystalline apalutamidenanoformed apalutamide